News

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Why patients are being forced to switch to a 2nd-choice obesity drug
CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...
CVS opts for Wegovy over Zepbound, affecting drug access for some
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
BioSpace4h
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
Is CVS Health Corporation (CVS) the Best Performing Healthcare Stock to Buy Now?
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other best ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
Trump Executive Order Could Reshape How Americans Pay for Drugs. Why It Isn’t Bad for Pharma Stocks.
The Trump administration’s Monday executive order could restructure how Americans buy prescription drugs, pushing them away ...